PT - JOURNAL ARTICLE AU - Ujjainia, Rajat AU - Tyagi, Akansha AU - Sardana, Viren AU - Naushin, Salwa AU - Bhatheja, Nitin AU - Kumar, Kartik AU - Barman, Joydeb AU - Prakash, Satyaratha AU - Kutum, Rintu AU - Bhaskar, Akash AU - Loomba, Menka AU - Khanna, Yukti AU - Walecha, Chestha AU - Ahmed, Rizwan AU - Yadav, Ashutosh AU - Bajaj, Archana AU - Malik, Gaurav AU - Qureshi, Sahar AU - Waghdhare, Swati AU - Siddiqui, Samreen AU - Trehan, Kamal Krishan AU - Mani, Manju AU - Dang, Rajiv AU - Das, Poonam AU - Dougall, Pankaj AU - Mahajan, Monica AU - Buddhiraja, Sandeep AU - Agrawal, Anurag AU - Dash, Debasis AU - Jha, Sujeet AU - Sengupta, Shantanu TI - Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2 AID - 10.1101/2021.02.28.21252621 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.28.21252621 4099 - http://medrxiv.org/content/early/2021/04/18/2021.02.28.21252621.short 4100 - http://medrxiv.org/content/early/2021/04/18/2021.02.28.21252621.full AB - The Oxford-Astra Zeneca COVID 19 vaccine (AZD1222 or ChAdOx1) is locally manufactured as Covishield by Serum Institute, Pune, India. In a group of 307 healthcare workers administered Covishield, we report measured antibody response to SARS-CoV-2 directed against the spike protein (S-antigen) at days 0, 7, 14, 28 and 45, with second dose on day 28 for all except 20 subjects who did not receive a second dose. In 129 subjects (42%) who had already developed antibodies to SARS-CoV-2 at day 0 (before immunization), it was observed that antibody response was significantly higher at each time point, with the maximum increase seen between days 0 and 7. The antibody levels and neutralizing activity in these subjects had peaked by day 28 and the second dose did not lead to further increase. Data from 9 subjects who were seropositive at baseline and received only one dose was similar to those who received both doses. In contrast the baseline sero-negative group (n=178) started developing antibody response only after 14 days or later. Administration of the second dose was associated with further increase in antibody levels at day 45 compared to day 28, with marked increase in neutralizing activity. In baseline seronegative subjects, who did not take the vaccine at day 28 (n=11), the antibody levels increased by about 2.5 folds between days 28 and 45, with minimal change in the neutralizing antibodies. In general, vaccination was well tolerated, and there were no group specific differences in post-vaccination symptomatology. Our data suggests that ChAdOx1 is highly immunogenic, particularly so where previous SARS CoV2 antibody-response is established. In such subjects, a single dose may be sufficient but in absence of such determination, both doses are required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Ethics Committee (Max healthcare Committee), New Delhi with separate approval for all sites CSIR-IGIB, New Delhi IHECAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified categorized data of the participants can be provided on request basis after approval of ethics committee of the institute/organisation to which the requesting person belongs, stating the potential need and usage and signing of an agreement with the corresponding authors on behalf of Max Hospital, Saket, New Delhi and CSIR-IGIB. The request could be made to the corresponding authors after 90 days of publication.